Life Cycle Investment Partners Ltd purchased a new stake in Stryker Corporation (NYSE:SYK – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 135,364 shares of the medical technology company’s stock, valued at approximately $47,576,000.
Several other hedge funds have also bought and sold shares of SYK. Corient Private Wealth LLC grew its position in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Alliancebernstein L.P. lifted its stake in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Strive Asset Management LLC bought a new position in Stryker during the 3rd quarter valued at $227,389,000. Credit Agricole S A bought a new position in Stryker during the 3rd quarter valued at $194,045,000. Finally, Pictet Asset Management Holding SA lifted its stake in Stryker by 190.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock valued at $163,878,000 after acquiring an additional 305,640 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Transactions at Stryker
In related news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on SYK
Stryker Trading Up 0.9%
NYSE SYK opened at $316.39 on Friday. The stock has a market capitalization of $121.29 billion, a price-to-earnings ratio of 36.62, a PEG ratio of 1.99 and a beta of 0.80. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s fifty day moving average is $325.22 and its 200-day moving average is $349.82.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 EPS for the current year.
Stryker Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
- Five stocks we like better than Stryker
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
